tetano
Editor, Senior Moderator
Pract Lab Med
. 2024 Apr 1:39:e00392.
doi: 10.1016/j.plabm.2024.e00392. eCollection 2024 Mar. Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience
Francesca Romano[SUP] 1 [/SUP], Luisa Lanzilao[SUP] 1 [/SUP], Edda Russo[SUP] 2 [/SUP], Maria Infantino[SUP] 3 [/SUP], Francesca Nencini[SUP] 1 [/SUP], Giovanni Cappelli[SUP] 2 [/SUP], Stefano Dugheri[SUP] 2 [/SUP], Mariangela Manfredi[SUP] 3 [/SUP], Alessandra Fanelli[SUP] 1 [/SUP], Amedeo Amedei[SUP] 2 [/SUP], Nicola Mucci[SUP] 2 [/SUP]
Affiliations
Objectives: Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical severity. A cytokine storm is associated with COVID-19 severity. Of these, IL-6 is significantly associated with higher mortality and is also a marker for predicting disease prognosis. IL-6 may act as a target for therapeutics and, a blockade of IL-6 function by Tocilizumab has been described as a treatment of the inflammatory process COVID-19-related. This study aims to describe our experience comparing two different methods, in detail Human IL-6 Instant ELISA and the Elecsys IL-6 based on ECLIA, for the IL-6 assessment.
Design and methods: IL-6 levels from serum samples of 104 COVID-19 patients, admitted to the AOU Careggi (Hospital in Florence -Italy), were assessed by using the two above-mentioned methods, and the results were analysed through Passing-Bablok regression fit and Bland-Altman plot.
Results: The regression exhibited a linear relation between the methods with a regression equation (y = - 0.13 + 0.63 x; 95 % C.I. intercept = - 0.13 to 4.55; 95 % C.I. slope = 1.03 to 1.26 with R[SUP]2[/SUP] = 0.89, p > 0.05), showing a positive slope. The agreement of the two methods reported a bias of -25.0 pg/mL. Thus, the two methods correlate but do not agree in terms of numeric results.
Conclusions: The two assays showed good comparability. However, because of the extremely wide linear range of the ECLIA, its throughput and its capacity for immune profiling, it represents an interesting emerging technology in the immunology field.
Keywords: COVID-19; ECLIA; ELISA; Interleukin-6.
. 2024 Apr 1:39:e00392.
doi: 10.1016/j.plabm.2024.e00392. eCollection 2024 Mar. Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: An Italian real-life experience
Francesca Romano[SUP] 1 [/SUP], Luisa Lanzilao[SUP] 1 [/SUP], Edda Russo[SUP] 2 [/SUP], Maria Infantino[SUP] 3 [/SUP], Francesca Nencini[SUP] 1 [/SUP], Giovanni Cappelli[SUP] 2 [/SUP], Stefano Dugheri[SUP] 2 [/SUP], Mariangela Manfredi[SUP] 3 [/SUP], Alessandra Fanelli[SUP] 1 [/SUP], Amedeo Amedei[SUP] 2 [/SUP], Nicola Mucci[SUP] 2 [/SUP]
Affiliations
- PMID: 38617587
- PMCID: PMC11015480
- DOI: 10.1016/j.plabm.2024.e00392
Objectives: Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical severity. A cytokine storm is associated with COVID-19 severity. Of these, IL-6 is significantly associated with higher mortality and is also a marker for predicting disease prognosis. IL-6 may act as a target for therapeutics and, a blockade of IL-6 function by Tocilizumab has been described as a treatment of the inflammatory process COVID-19-related. This study aims to describe our experience comparing two different methods, in detail Human IL-6 Instant ELISA and the Elecsys IL-6 based on ECLIA, for the IL-6 assessment.
Design and methods: IL-6 levels from serum samples of 104 COVID-19 patients, admitted to the AOU Careggi (Hospital in Florence -Italy), were assessed by using the two above-mentioned methods, and the results were analysed through Passing-Bablok regression fit and Bland-Altman plot.
Results: The regression exhibited a linear relation between the methods with a regression equation (y = - 0.13 + 0.63 x; 95 % C.I. intercept = - 0.13 to 4.55; 95 % C.I. slope = 1.03 to 1.26 with R[SUP]2[/SUP] = 0.89, p > 0.05), showing a positive slope. The agreement of the two methods reported a bias of -25.0 pg/mL. Thus, the two methods correlate but do not agree in terms of numeric results.
Conclusions: The two assays showed good comparability. However, because of the extremely wide linear range of the ECLIA, its throughput and its capacity for immune profiling, it represents an interesting emerging technology in the immunology field.
Keywords: COVID-19; ECLIA; ELISA; Interleukin-6.